Genmab — Januar 2018
-
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens https://clinicaltrials.gov/ct2/show/NCT03412565?term=daratumumab+OR+ofatumumab&lupd_s=01%2F25%2F2018&rank=4
-
Det går squ´meget godt nu
-
Som sagt før " Genmab er som en rutschebane i Fårup...det går SÅ hurtigt ned og OP
-
Vi kan vist stadig være enig om at shorterne i aktien er meget venlige og humane. Vi ser absolut ingen aggressivitet og forsøg på at trykke kursen ned under støttepunkter og udløse stop loses over en bred kam.
-
Enig med Pensionisten. Der er udmattelse at spore. Det har vi dog prøvet før gennem årene.
-
Jeg formoder, at vi kursmæssigt danner base for øjeblikket. Nyorienteringen starter så efter næste Q&A d. 22. februar.
-
Hmmm… i actually think bears have done well again this week; I think there was plenty down pressure Tuesday and yesterday morning and we close the week way below the weekly high…. In this huge bull market where everything seems to be going through the roof and makes new highs Genmab needs another 30% to even get there…
-
Anyways, TA: The 1194.5 high last week was just shy of the 38.2% retracement from the 1015 low. Yesterday we almost hit the 61.8% retracement of that level (1084). If we manage to hold that, an equal leg move (ab=cd) would get us to 1269. Note that the 1240-1250 area was resistance in november and early december. 1252 is the 50% retracement from the 1015 low.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind